Citigroup’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.88M | Buy |
75,118
+43,902
| +141% | +$2.24M | ﹤0.01% | 2157 |
|
|
2025
Q4 | $1.55M | Sell |
31,216
-33,500
| -52% | -$1.63M | ﹤0.01% | 2821 |
|
|
2025
Q3 | $3.09M | Sell |
64,716
-52,852
| -45% | -$2.13M | ﹤0.01% | 2330 |
|
|
2025
Q2 | $3.71M | Buy |
117,568
+27,523
| +31% | +$882K | ﹤0.01% | 2127 |
|
|
2025
Q1 | $2.95M | Buy |
90,045
+9,034
| +11% | +$320K | ﹤0.01% | 2364 |
|
|
2024
Q4 | $2.93M | Buy |
81,011
+3,572
| +5% | +$126K | ﹤0.01% | 2478 |
|
|
2024
Q3 | $2.41M | Buy |
77,439
+22,623
| +41% | +$706K | ﹤0.01% | 2497 |
|
|
2024
Q2 | $1.47M | Buy |
54,816
+9,727
| +22% | +$282K | ﹤0.01% | 2601 |
|
|
2024
Q1 | $1.54M | Buy |
45,089
+813
| +2% | +$24.2K | ﹤0.01% | 2662 |
|
|
2023
Q4 | $1.28M | Buy |
44,276
+16,253
| +58% | +$431K | ﹤0.01% | 2625 |
|
|
2023
Q3 | $773K | Sell |
28,023
-21,395
| -43% | -$651K | ﹤0.01% | 2719 |
|
|
2023
Q2 | $1.49M | Buy |
49,418
+14,538
| +42% | +$509K | ﹤0.01% | 2507 |
|
|
2023
Q1 | $1.26M | Sell |
34,880
-8,127
| -19% | -$312K | ﹤0.01% | 2379 |
|
|
2022
Q4 | $1.53M | Buy |
43,007
+6,500
| +18% | +$226K | ﹤0.01% | 2250 |
|
|
2022
Q3 | $1.24M | Buy |
36,507
+3,083
| +9% | +$100K | ﹤0.01% | 2553 |
|
|
2022
Q2 | $966K | Sell |
33,424
-19,300
| -37% | -$553K | ﹤0.01% | 2686 |
|
|
2022
Q1 | $1.7M | Buy |
52,724
+5,826
| +12% | +$179K | ﹤0.01% | 2501 |
|
|
2021
Q4 | $1.37M | Sell |
46,898
-3,771
| -7% | -$114K | ﹤0.01% | 2941 |
|
|
2021
Q3 | $1.35M | Buy |
50,669
+434
| +0.9% | +$11.6K | ﹤0.01% | 2854 |
|
|
2021
Q2 | $1.55M | Buy |
50,235
+29,877
| +147% | +$916K | ﹤0.01% | 2878 |
|
|
2021
Q1 | $534K | Sell |
20,358
-6,074
| -23% | -$170K | ﹤0.01% | 3398 |
|
|
2020
Q4 | $666K | Sell |
26,432
-11,921
| -31% | -$257K | ﹤0.01% | 3954 |
|
|
2020
Q3 | $799K | Sell |
38,353
-13,900
| -27% | -$315K | ﹤0.01% | 3473 |
|
|
2020
Q2 | $1.24M | Buy |
52,253
+17,130
| +49% | +$378K | ﹤0.01% | 3324 |
|
|
2020
Q1 | $632K | Sell |
35,123
-27,997
| -44% | -$588K | ﹤0.01% | 3649 |
|
|
2019
Q4 | $1.5M | Buy |
63,120
+13,875
| +28% | +$337K | ﹤0.01% | 3310 |
|
|
2019
Q3 | $1.35M | Sell |
49,245
-2,818
| -5% | -$83.5K | ﹤0.01% | 3304 |
|
|
2019
Q2 | $1.72M | Buy |
52,063
+2,606
| +5% | +$89.3K | ﹤0.01% | 3032 |
|
|
2019
Q1 | $1.73M | Buy |
49,457
+18,659
| +61% | +$694K | ﹤0.01% | 2807 |
|
|
2018
Q4 | $1.02M | Sell |
30,798
-38,383
| -55% | -$1.65M | ﹤0.01% | 3379 |
|
|
2018
Q3 | $3.48M | Buy |
69,181
+32,257
| +87% | +$1.59M | ﹤0.01% | 2201 |
|
|
2018
Q2 | $2.21M | Sell |
36,924
-85,849
| -70% | -$4.45M | ﹤0.01% | 2603 |
|
|
2018
Q1 | $5.62M | Sell |
122,773
-8,052
| -6% | -$336K | ﹤0.01% | 1664 |
|
|
2017
Q4 | $5.21M | Sell |
130,825
-9,270
| -7% | -$366K | ﹤0.01% | 1799 |
|
|
2017
Q3 | $5.6M | Sell |
140,095
-10,081
| -7% | -$436K | ﹤0.01% | 1659 |
|
|
2017
Q2 | $6.47M | Buy |
150,176
+79,203
| +112% | +$2.82M | 0.01% | 1482 |
|
|
2017
Q1 | $2.22M | Sell |
70,973
-33,507
| -32% | -$898K | ﹤0.01% | 2373 |
|
|
2016
Q4 | $2.64M | Buy |
104,480
+53,691
| +106% | +$1.2M | ﹤0.01% | 2605 |
|
|
2016
Q3 | $1.26M | Buy |
50,789
+22,589
| +80% | +$511K | ﹤0.01% | 2977 |
|
|
2016
Q2 | $574K | Sell |
28,200
-2,651
| -9% | -$47K | ﹤0.01% | 3509 |
|
|
2016
Q1 | $471K | Buy |
30,851
+25,153
| +441% | +$328K | ﹤0.01% | 4187 |
|
|
2015
Q4 | $77K | Buy |
5,698
+423
| +8% | +$6.54K | ﹤0.01% | 5588 |
|
|
2015
Q3 | $73K | Buy |
5,275
+1,375
| +35% | +$25.6K | ﹤0.01% | 5179 |
|
|
2015
Q2 | $66K | Sell |
3,900
-4,364
| -53% | -$62.1K | ﹤0.01% | 5322 |
|
|
2015
Q1 | $100K | Sell |
8,264
-6,667
| -45% | -$63K | ﹤0.01% | 5026 |
|
|
2014
Q4 | $124K | Buy |
14,931
+12,179
| +443% | +$102K | ﹤0.01% | 5070 |
|
|
2014
Q3 | $24K | Buy |
2,752
+2,505
| +1,014% | +$22.6K | ﹤0.01% | 5799 |
|
|
2014
Q2 | $3K | Sell |
247
-5,571
| -96% | -$49.6K | ﹤0.01% | 6643 |
|
|
2014
Q1 | $52K | Sell |
5,818
-5,166
| -47% | -$47.6K | ﹤0.01% | 5464 |
|
|
2013
Q4 | $83K | Buy |
10,984
+4,499
| +69% | +$31.5K | ﹤0.01% | 5387 |
|
|
2013
Q3 | $48K | Buy |
6,485
+5,857
| +933% | +$39.3K | ﹤0.01% | 5315 |
|
|
2013
Q2 | $4K | Buy |
+628
| New | +$3.7K | ﹤0.01% | 6397 |
|
Other funds holding SUPN
VPM
VCM
NAMI
AC
Citigroup's SUPN Position: Q1 2026 in Review
Citigroup increased its Supernus Pharmaceuticals (SUPN) stake by 141% in Q1 2026, buying an estimated $2.24M and bringing the position to 75,118 shares worth $3.88M. The position accounts for ﹤0.01% of the portfolio, ranked #2157.
Citigroup first reported a position in SUPN in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.47M in Q2 2017. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.
- Citigroup held 75,118 shares of Supernus Pharmaceuticals worth $3.88M as of Q1 2026.
- Citigroup bought 43,902 Supernus Pharmaceuticals shares in Q1 2026, an estimated $2.24M.
- Supernus Pharmaceuticals made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2157 holding.
- Citigroup first reported a position in Supernus Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Supernus Pharmaceuticals position peaked at $6.47M in Q2 2017.
- 327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.